Ahlstrom Launches ChemoGard BVB Fabric for Safer Chemotherapy Drug Handling

Ahlstrom has introduced ChemoGard BVB fabric, a new protective apparel material designed for healthcare environments where chemotherapy drugs are handled, prepared or administered.

The launch is relevant for hospitals, oncology departments, laboratories and operating rooms looking for protective apparel materials that balance barrier performance with wearer comfort. Recent industry coverage describes ChemoGard BVB as a breathable fabric for chemotherapy drug handling, combining AAMI Level 4 viral barrier protection, chemotherapy drug resistance and a lightweight tri-laminate construction. 

Why this launch matters

Healthcare professionals who handle hazardous drugs need protection that works across more than one risk category. Chemotherapy drugs can present occupational exposure risks, while clinical settings may also require liquid and viral barrier performance.

NIOSH states that healthcare workers who handle hazardous drugs may face health risks and that employers should provide appropriate personal protective equipment for those workers. (CDC) This makes the choice of gown and apparel materials a practical safety issue, not just a product specification.

ChemoGard BVB fabric is positioned to address that need at the material level. Instead of focusing only on fluid barrier or only on comfort, Ahlstrom’s new fabric brings together breathability, viral barrier protection and chemotherapy drug resistance in one construction.

Key features of ChemoGard BVB fabric

According to recent product information, ChemoGard BVB fabric offers:

Breathable comfort: The fabric is designed to support wearers in demanding healthcare environments where protective apparel may need to be worn for extended periods.

AAMI Level 4 viral barrier protection: AAMI Level 4 is the highest barrier-performance level under the ANSI/AAMI PB70 classification system for protective apparel and drapes. CDC’s PPE-Info database notes that AAMI PB70 defines four levels of barrier performance, from Level 1 as the lowest to Level 4 as the highest. (CDC)

Chemotherapy drug resistance: Ahlstrom says the fabric has been tested in accordance with ASTM D6978 chemotherapy permeation standards and provides up to 240 minutes of protection against hazardous chemotherapy drugs such as Carmustine. (Pulpaper News)

Low-lint construction: Low lint is important in clinical and laboratory environments where particle control can affect cleanliness, workflow and contamination risk.

No intentionally added PFAS: The fabric is described as being made without intentionally added PFAS, aligning with increasing market and regulatory attention around PFAS reduction in performance materials. (Ahlstrom)

A lightweight tri-laminate approach

ChemoGard BVB fabric uses a lightweight tri-laminate construction. In practical terms, this means the material is built to combine multiple performance layers into a single fabric solution.

For healthcare apparel developers, this matters because protective garments need to do more than pass a single test. They must be suitable for clinical use, support mobility, limit exposure risk and remain tolerable for staff during long procedures or preparation tasks.

A fabric that is too heavy or uncomfortable can create usability problems. A fabric that is comfortable but lacks sufficient barrier performance may not be appropriate for higher-risk environments. ChemoGard BVB is being positioned between those competing needs: reliable protection with breathable wearability.

Designed for chemotherapy handling environments

Ahlstrom identifies the fabric as suitable for protective apparel used in clinical, laboratory and operating room environments where chemotherapy drugs may be handled. (Ahlstrom)

That distinction is important. ChemoGard BVB is a fabric for protective apparel, not a finished gown or a complete PPE system by itself. Final garment performance can still depend on design, seams, closures, fit, manufacturing quality, labeling and the specific risk assessment of the healthcare setting.

Hospitals and apparel manufacturers should therefore evaluate the finished product, not just the base material, before selecting apparel for chemotherapy handling protocols.

How it fits into broader PPE requirements

AAMI Level 4 protection is commonly associated with high-risk exposure scenarios. The FDA explains that medical gowns rely on defined critical zones of protection and that seams must provide the same liquid barrier protection as the rest of the gown for the level claimed. (U.S. Food and Drug Administration)

This is why material innovation is only one part of PPE performance. A high-performing fabric still needs to be converted into garments that preserve protection across seams, cuffs, closures and other vulnerable areas.

For oncology and hospital procurement teams, the most relevant questions are likely to be:

Does the finished garment meet the required barrier level?

Has the apparel been tested against the specific chemotherapy drugs used in the facility?

Is the gown comfortable enough for real clinical workflows?

Does the product support current sustainability or restricted-substance requirements?

ChemoGard BVB appears designed to help apparel manufacturers answer more of these questions with one material platform.

The PFAS angle

The statement that ChemoGard BVB is made without intentionally added PFAS may be significant for healthcare buyers and product developers. PFAS have come under growing scrutiny because of persistence and environmental concerns, and many industries are looking for alternatives in barrier and performance applications.

For medical textiles, this is especially complex. Protective apparel must meet demanding performance requirements, so material changes cannot compromise safety. A fabric that avoids intentionally added PFAS while still targeting viral barrier and chemotherapy resistance may therefore appeal to manufacturers balancing compliance, sustainability and clinical protection.

What healthcare buyers should verify

Before adopting any new protective apparel material or finished garment, buyers should request complete technical documentation. Useful checks include:

Barrier-performance data for the finished garment

Chemotherapy permeation test results and drug-specific breakthrough times

AAMI PB70 classification documentation

Information on seams, closures and critical zones

Instructions for use and intended-use limitations

Confirmation of PFAS-related claims

Compatibility with existing hazardous-drug handling procedures

This approach helps avoid overinterpreting a material claim as a full PPE-system claim.  ChemoGard BVB fabric

Bottom line

Ahlstrom’s ChemoGard BVB fabric adds a new option for manufacturers developing protective apparel for chemotherapy handling environments. Its main value proposition is the combination of breathable comfort, AAMI Level 4 viral barrier protection, chemotherapy drug resistance, low-lint construction and no intentionally added PFAS.

For healthcare settings, the launch reflects a broader trend: protective apparel is expected to do more than block fluids. It must support staff safety, clinical performance, comfort and evolving material requirements at the same time.

ChemoGard BVB fabric does not replace facility-level risk assessment or finished-garment validation, but it gives apparel developers a new material platform for high-protection chemotherapy handling applications.

Andritz Unveils Sustainable Nonwovens and Recycling Technologies at INDEX 26

---